Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital.
Pinet S, Durand S, Perani A, Darnaud L, Amadjikpe F, Yon M, Darbas T, Vergnenegre A, Egenod T, Simonneau Y, Le Brun-Ly V, Pestre J, Venat L, Thuillier F, Chaunavel A, Duchesne M, Fermeaux V, Guyot A, Lacorre S, Bessette B, Lalloué F, Durand K, Deluche E. Pinet S, et al. Among authors: egenod t. Front Oncol. 2023 Feb 27;13:1104659. doi: 10.3389/fonc.2023.1104659. eCollection 2023. Front Oncol. 2023. PMID: 36923436 Free PMC article.
Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers.
Dusselier M, Deluche E, Delacourt N, Ballouhey J, Egenod T, Melloni B, Vergnenègre C, Veillon R, Vergnenègre A. Dusselier M, et al. Among authors: egenod t. PLoS One. 2019 Jul 17;14(7):e0219060. doi: 10.1371/journal.pone.0219060. eCollection 2019. PLoS One. 2019. PMID: 31314761 Free PMC article.
Two-Stage Bronchoscopic Endobronchial Valve Treatment Can Lead to Progressive Lung Volume Reduction and May Decrease Pneumothorax Risk.
Egenod T, Tricard J, Fumat R, Simonneau Y, Favard F, Guillot MS, Collot S, Dupuis M, Melloni B, Vergnenegre A, Guibert N, Dusselier M. Egenod T, et al. Int J Chron Obstruct Pulmon Dis. 2021 Jun 28;16:1957-1965. doi: 10.2147/COPD.S307829. eCollection 2021. Int J Chron Obstruct Pulmon Dis. 2021. PMID: 34234426 Free PMC article.
Bilateral endobronchial valves treatment for severe emphysema.
Guibert N, Fumat R, Dupuis M, Dusselier M, Favard F, Heluain V, Mallah S, Barthes R, Simonneau Y, Egenod T. Guibert N, et al. Among authors: egenod t. ERJ Open Res. 2022 Apr 11;8(2):00672-2021. doi: 10.1183/23120541.00672-2021. eCollection 2022 Apr. ERJ Open Res. 2022. PMID: 35415190 Free PMC article.
Effectiveness and safety of nivolumab in the treatment of lung cancer patients in France: preliminary results from the real-world EVIDENS study.
Barlesi F, Dixmier A, Debieuvre D, Raspaud C, Auliac JB, Benoit N, Bombaron P, Moro-Sibilot D, Audigier-Valette C, Asselain B, Egenod T, Rabeau A, Fayette J, Sanchez ML, Labourey JL, Westeel V, Lamoureux P, Cotte FE, Allan V, Daumont M, Dumanoir J, Reynaud D, Calvet CY, Ozan N, Pérol M. Barlesi F, et al. Among authors: egenod t. Oncoimmunology. 2020 Apr 12;9(1):1744898. doi: 10.1080/2162402X.2020.1744898. Oncoimmunology. 2020. PMID: 33457089 Free PMC article. Clinical Trial.
Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
Girard N, Galland-Girodet S, Avrillon V, Besse B, Duruisseaux M, Cadranel J, Otto J, Prevost A, Roch B, Bennouna J, Bouledrak K, Coudurier M, Egenod T, Lamy R, Ricordel C, Moro-Sibilot D, Odier L, Tillon-Strozyk J, Zalcman G, Missy P, Westeel V, Baldacci S. Girard N, et al. Among authors: egenod t. ESMO Open. 2022 Apr;7(2):100418. doi: 10.1016/j.esmoop.2022.100418. Epub 2022 Feb 26. ESMO Open. 2022. PMID: 35227966 Free PMC article.
20 results